期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 54, 期 1, 页码 191-196出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00976-09
关键词
-
资金
- NIH/NIAID [NO1-AI-05415]
- China Ministry of Science and Technology [2003AA219033, 2003AA001043]
- Chongqing Science and Technology Commission
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005415, N01AI005418] Funding Source: NIH RePORTER
The clinical application of conventional peptide drugs often is limited by their short in vivo half-life and potential immunogenicity. Frequent injection presents challenges to the treatment of chronic diseases, such as HIV infection. We chemically modified a peptide HIV fusion inhibitor with 3-maleimidopropionic acid (MPA), which allows rapid and irreversible conjugation with serum albumin at a 1: 1 molar ratio. FB006M, with an MPA modification at the 13th amino acid, rapidly formed conjugate with albumin upon intravenous injection, and it exhibited a remarkably extended in vivo half-life. The albumin conjugate of FB006M displayed potent inhibitory activity against a number of laboratory and clinical isolates of HIV-1 in vitro and in vivo. No immunogenicity or antibody formation was detected after repeated dosing. The clinical application of FB006M may decrease the cost of treatment and improve treatment compliance and patient quality of life.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据